Novartis Data Show Potential of Remibrutinib as an Oral Treatment for Chronic Spontaneous Urticaria Providing Significant Symptom Improvement as Early as Week 2
In pivotal Phase III trials, remibrutinib– a highly selective, oral Bruton’s tyrosine kinase inhibitor– demonstrated clinically meaningful and statistically significant reduction in urticaria activity vs placebo1
Treatment...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials